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Abstract
Background: There is limited guidance on the design of stepped wedge cluster randomised trials. Current
methodological literature focuses mainly on trials with cross-sectional data collection at discrete times, yet many
recent stepped wedge trials do not follow this design. In this article, we present a typology to characterise the full
range of stepped wedge designs, and offer guidance on several other design aspects.
Methods: We developed a framework to define and report the key characteristics of a stepped wedge trial,
including cluster allocation and individual participation. We also considered the relative strengths and weaknesses
of trials according to this framework. We classified recently published stepped wedge trials using this framework
and identified illustrative case studies. We identified key design choices and developed guidance for each.
Results: We identified three main stepped wedge designs: those with a closed cohort, an open cohort, and a
continuous recruitment short exposure design. In the first two designs, many individuals experience both control
and intervention conditions. In the final design, individuals are recruited in continuous time as they become eligible
and experience either the control or intervention condition, but not both, and then provide an outcome measurement
at follow-up. While most stepped wedge trials use simple randomisation, stratification and restricted randomisation are
often feasible and may be useful. Some recent studies collect outcome information from individuals exposed a long
time before or after the rollout period, but this contributes little to the primary analysis. Incomplete designs should be
considered when the intervention cannot be implemented quickly. Carry-over effects can arise in stepped wedge trials
with closed and open cohorts.
Conclusions: Stepped wedge trial designs should be reported more clearly. Researchers should consider the use of
stratified and/or restricted randomisation. Trials should generally not commit resources to collect outcome data from
individuals exposed a long time before or after the rollout period. Though substantial carry-over effects are uncommon
in stepped wedge trials, researchers should consider their possibility before conducting a trial with closed or open
cohorts.
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Background
Stepped wedge cluster randomised trials (SWTs) are
becoming increasing popular and are being applied to
a growing range of interventions, as shown in our re-
view article [1]. However, SWTs encompass a broad
range of designs, and the methodological literature is
lagging behind the growth in the conduct of SWTs.
Much of the literature to date has focussed on a small
range of SWT designs where data are collected from
individuals at discrete time points, and individuals
contribute one measurement during the study [2–5].
This may, for example, arise from cross-sectional sam-
pling from all clusters just before each crossover point
(whenever a group of clusters changes from control to
intervention condition). However, most SWTs de-
scribed in the recent literature do not follow this par-
ticular design [1]. Consequently, there is limited
published guidance for planning SWTs, and adapting
the published guidance to the broad range of designs
in use is not straightforward.
Researchers planning SWTs must consider a range
of design issues, starting with how individuals from
within clusters will participate. The design literature
makes little distinction between SWTs where individ-
uals are exposed to one condition only, or to both
control and intervention conditions. The literature has
also not clearly addressed the role of data collected
before and/or after the rollout period in the study.
The limited range of designs considered has also ham-
pered the growth of terminology to describe the con-
duct of SWTs, and allow them to be reported in a
transparent and consistent way, though others have
begun this process [6].
In this paper we formally define the characteristics of
SWTs, including aspects of the cluster allocation strat-
egy for an SWT, and describe the range of ways in
which individuals might participate in terms of expos-
ure and measurements. We describe which key aspects
should be reported and the role of graphical presenta-
tion. We review recent SWTs to identify the most
commonly conducted designs and illustrate each with
a case study. We describe which designs we think pro-
vide high quality evidence and those where the poten-
tial for bias, principally from carry-over effects, should
be carefully considered and investigated. Cluster defin-
ition, individual exposure, and participation are largely
determined by the research question and setting. We
describe and guide the key design choices in planning
an SWT: the randomisation method, the number of
steps and length of time between successive crossover
points, whether the trial will be complete or incom-
plete, and whether data shall be collected before or
after the rollout period. Sample size is the topic of an-
other article in this series [7].
Methods
We developed a framework and terminology by which
to define the key characteristics of an SWT and the
cluster allocation. We then developed a typology of in-
dividual exposure and measurement, and with that in
mind, examined the recently published SWTs reviewed
in this series [1] to identify commonly used designs and
illustrative case studies. We considered the strengths
and weaknesses of the commonly used designs, focus-
sing on the possibility of carry-over effects. We identi-
fied the key design choices for an SWT and developed
guidance for each one. We also considered how the
design of an SWT can be clearly reported. The work
presented here did not require ethical approval as it
involves only critical thinking and review of published
research articles.
Results
Defining characteristics of stepped wedge cluster
randomised trials, allocation and terminology
An SWT is a trial in which clusters receive the interven-
tion at different time points, the order in which they
receive it is randomised, and data are collected from
clusters over time.
Figure 1 identifies the key features that define the
allocation strategy for an SWT. SWTs randomly allo-
cate clusters to groups that cross over from a control
condition to an intervention at different crossover
points (b). Key aspects of the allocation strategy are
the number of clusters per group (d), the number of
groups (e), and the length of time between successive
crossover points, sometimes referred to informally as
the ‘step length’ (h), which together also determine
the total number of clusters (f ) and total trial dur-
ation (a). In Figure 1 there are four groups, each with
two clusters. We define a step in the design to be
both a crossover point and the time to the subse-
quent crossover point (c).
SWTs can have up to three main phases. For all
SWTs data will be collected during a rollout period
(j), in which groups of clusters are crossing over from
the control condition (often standard care or policy)
to the intervention condition. At any one time during
this period, some clusters are allocated to the inter-
vention condition while others are not. In SWTs
there may also be periods of data collection before
the rollout period (g) and/or after the rollout period
(i). In some trials, individuals are exposed to the con-
trol and/or intervention condition within the trial,
but are then measured later after a (potentially long)
follow-up period. In such trials we consider outcome
data from individuals exposed before, during, or after
rollout to be ‘collected’ before, during, or after
rollout.
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Typology of individual exposure to intervention and
control conditions and measurement
Like other cluster randomised trials (CRTs), SWTs are
generally designed to study the effects of a new interven-
tion, such as a policy or staff training programme which
is implemented at the cluster level, but experienced and
measured by its impact on individuals. For example, in a
situation where hospital staff implement a new patient
management policy, the SWT is designed to establish
whether this leads to better outcomes for patients who
are treated at the hospital.
Whilst the clusters in an SWT normally participate
throughout the trial, experiencing control and interven-
tion conditions at different times according to the alloca-
tion strategy, the ways in which individuals are exposed
and participate vary greatly between trials. For example, in
some SWTs, all individuals participate in the trial from
start to end and experience both control and intervention
conditions. In other SWTs, all individuals who participate
experience either the control or intervention for only a
brief exposure period (for example, a hospital appoint-
ment), and the outcome may be measured after a follow-
up period, that is, a period in which individuals are no
longer exposed to the control or intervention condition
but are still required to participate in order to measure
the effect of the intervention. These features of how indi-
viduals participate normally reflect how such individuals
experience treatments and/or policies in the wider popula-
tion outside the trial, and how they become eligible and
cease being eligible in the population, for example how
they first attend hospital and how they are discharged
from care. These features are often outside the control of
the trialists, but influence how SWTs are designed. In
some SWTs, all participating individuals contribute one or
more outcome measurements. In other SWTs where large
clusters (such as cities) are randomised, then only a small
Fig. 1 Characteristics and terminology of stepped-wedge cluster randomised controlled trials, where shaded areas indicate intervention exposure
and unshaded areas indicate control exposure
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fraction of the participants may be invited to provide
outcome measurements, for example by a questionnaire
survey.
In order for SWT designs to be fully reported and to en-
able readers to judge their strengths and weaknesses, it is
important to describe how individuals participate in a trial,
how they are exposed to control and/or intervention con-
ditions, and how measurements are obtained. In a recent
article, Hemming et al. described three SWT designs, but
these mainly considered how measurements are obtained
from individuals, and not features of participation or ex-
posure [8]. We first describe three common designs for
SWTs identified in our review of 37 trials, then briefly out-
line characteristics by which the individual participation
exposure and measurement can be identified and reported
in an SWT. In the supplementary table of our review [1],
each SWT is assigned to one of these three designs, aside
from two trials following non-standard designs described
later. For each design we offer one detailed example from
the review.
Three main stepped wedge cluster randomised trial
designs: individual exposure and measurement
Continuous recruitment with short exposure
Thirteen of the trials included in our review used this
design. Few (or even no) individuals participate as the trial
begins, but more become eligible and participate over
time, and are then exposed for a short period. The out-
come is often measured after a follow-up period. Figure 2a
illustrates exposure and measurement for the design. The
middle participant is exposed only to the control condi-
tion, although the outcome is recorded after the cluster
has crossed over to the intervention condition. Single
measurement, repeated measurements or time-to-event
from the start of the individual’s exposure may be
chosen to assess outcomes, depending on the research
question.
Case study one Poldervaart et al. are conducting a trial
to investigate the effect of introducing a policy promot-
ing the use of a scoring system to guide clinical deci-
sions for patients with acute chest pain on arrival at
hospital emergency departments [9]. Ten hospitals were
randomised, and one additional hospital implemented
the intervention in each of 10 consecutive months (see
Fig. 3a). Besides data collection during the rollout
period, data were collected in the control condition from
all hospitals for the first month of the trial, and from all
hospitals once in the intervention condition in the final
month. The primary outcome measured is the occur-
rence of a major adverse cardiac event within six weeks
from presentation at hospital. The published protocol
does not state whether patients may participate more
than once in the trial, nor exactly what might happen to
patients presenting just before a hospital changes to the
intervention condition. However, as the exposure of the
patient primarily relates to their management within
the first few hours of arrival at hospital, it would seem
that nearly all participants will be exposed to the con-
trol or intervention condition, and not both.
Closed cohort
Our review identified 11 trials with a closed cohort design.
All participants are identified at the onset of the trial and
participate from start till end, typically without any chan-
ging clusters. Repeated measurements are typically taken
from the same individuals to assess change and its relation
to exposure. Figure 2b illustrates a closed cohort design
where individuals are measured repeatedly.
Case study two Mhurchu et al. investigated the effect of
providing free school breakfasts on pupils’ attendance
[10]. Fourteen schools participated, and each school pro-
vided a closed cohort of pupils for one school year
(Fig. 3b). After randomisation at the start of the school
year, the intervention was rolled out to groups of three to
four schools over four steps of length 2.5 months each
(school terms). The primary outcome, school attendance,
was assessed for each child and each term using a binary
outcome indicating whether attendance was less than
95 % of that expected. No outcome data were collected
when all of the clusters were in the control condition, but
some were collected during the final term when all schools
were in the intervention condition.
Open cohort
Our review identified 11 trials using an open cohort design.
With this design, a substantial number of individuals are
identified and participate from the start, but some may
leave during the trial and others may become eligible and
be exposed for some time. A minority of individuals may
also change between trial clusters. Most participants will
be exposed to both control and intervention conditions
during the trial. Repeated measurements from the same in-
dividuals could be taken at times relating to their individual
start of exposure, or researchers may choose to use a time-
to-event outcome. However, these choices may be prob-
lematic in some trials due to individuals leaving the cohort
over time, resulting in missing data. It is more common to
use cross-sectional sampling of individuals at pre-specified
times to provide data on the outcome of interest. Figure 2c
illustrates exposure and measurement for an open cohort.
In this case some individuals contribute more than one
measurement. In other settings where clusters are large
(such as cities), then only a very small proportion of partic-
ipants are sampled for outcome measurement at each time,
so individuals are measured once at most.
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Fig. 2 Diagrams to represent the exposure and timing of measurement for three illustrative participants in each of three main designs: a the
continuous recruitment short exposure design; b the closed cohort design with five measurements per participant, c the open cohort design
with one to three measurements per participant
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Case study three Fuller et al. investigated the effect that
providing feedback about hand hygiene to doctors and
nurses would have on their compliance with protocol [11].
The study randomised 16 hospitals in groups of two to
four to begin the intervention at one of five steps, with a
median step length of two months and a total rollout
period of nine months (Fig. 3c). Outcome data came from
observations of staff compliance carried out every six
weeks over the study period, and collected at the hospital
ward level. The timing of these measurements does not
seem to be linked to the trial steps or other aspects of the
design. While it is not reported directly, we assume that
there would be staff turnover during the trial as it is rela-
tively long, and so we view this as an SWT with an open
cohort design. Although the intervention is ‘delivered’ to
staff, the outcome measurement is collected for a ward
and pooled across the staff working the shift at that time.
Data are collected over 39 months, including nine months
before the rollout and 21 months after rollout has
completed. Hence most of the period of data collection
does not relate to the rollout period, which provides
the most direct information concerning the effect of
the intervention.
Our review also identified two trials with different designs
to those described above. The first was conducted by Stern
et al., and could be characterised as having continuous
recruitment followed by long and varying periods of ex-
posure [12]. The other trial by Williams et al. involved
Fig. 3 Diagrams to represent the rollout process in each of the three case studies, where shaded areas indicate intervention exposure and
unshaded areas indicate control exposure: a case study one, b case study two, c case study three
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measurement only of patients first exposed shortly be-
fore a crossover point, and they are seemingly exposed
to intervention or control, but not both [13].
In the introduction we mentioned that the design lit-
erature has focussed mainly on designs where measure-
ments are obtained cross-sectionally at predefined
discrete time points [2–5]. Now that we have outlined a
range of SWT designs, we see that amongst recent trials
the design literature mainly addresses two special cases:
the open cohort design with only a very small propor-
tion of participants sampled at each time point (so that
participants are measured at most once), and the design of
Williams et al. [13].
How to describe exposure and measurement in a stepped
wedge cluster randomised trial
We recommend that the design of an SWT should be
described in terms of how individuals are exposed, in-
cluding the start and duration of exposure, and whether
some, all, or no individuals experience both the control
and intervention, and how outcome measurements are
obtained. Examples of each are given below.
Timing of start of exposure (T)
1. All individuals are exposed from the start.
2. Many individuals are exposed from the start, but
some are first exposed later at various time points.
3. Groups of individuals are first exposed at one of a
number of discrete time points.
4. No individuals are exposed at the start and they are
first exposed in a continuous and gradual process.
Duration of exposure (D)
1. Through to close of trial.
2. Varying lengths across individuals.
3. Fixed length.
Measurement (M)
1. Repeated measurements from individuals, at fixed
calendar times, possibly linked to the timing of the
trial steps.
2. Repeated measurements from individuals, at times
linked to the start of their individual exposure, for
example at the start of exposure and at the end.
3. Cross-sectional measurement, at fixed calendar
time(s), possibly linked to the timing of trial steps.
This includes scenarios with repeated sampling at a
low proportion from big clusters, so only a few
individuals are sampled more than once.
4. Single measurement from each individual, at a
certain time after the start of their exposure.
5. Time-to-event, where time begins at the start of
exposure.
6. Number of events in an exposure period.
Referring back to our three main designs, we see that in
this typology a closed cohort is typically T1/D1/M1. An
open cohort with repeated cross-sectional sampling for
outcome measurement is T2/D2/M3. The continuous
recruitment short exposure period design is T4/D3 with
either M4, M2, or M5. Given the timing and duration of
exposure, there are often multiple choices of outcome
measure types and data collection methods, but some
would be inefficient or inappropriate. For example, cross-
sectional measurement to assess change within a closed
cohort (T1/D1/M3) is less sensitive than measuring the
same individuals.
Design choice one: number and length of steps
Trialists must choose the number of steps and the time
between successive crossover points (or step length) with
the total trial duration and sample size requirements in
mind. Here we assume a complete design, meaning that
data are collected from each cluster throughout the trial.
In the next section we consider incomplete designs and
analysis approaches, which can allow more flexible choice
of the length and number of steps.
At least in the case of cross-sectional sampling and
standard analysis methods, greater power is achieved with
a higher number of steps [7], reaching a maximum when
the size of each group is one cluster. Furthermore, in
some trials it may be impossible to implement the inter-
vention in more than one cluster at a time. However, con-
versely in other trials logistical constraints may prevent
this, for example because each crossover point may induce
training or other costs. In a closed cohort or open cohort
SWT it is often desired to take measurements just before
each crossover point, so a high number of steps may imply
more measurement points and hence greater costs. In a
closed cohort trial, in particular, this may also imply a
high measurement burden on individual participants,
and there may be little marginal gain in information
from excessively increasing the number of measurements
per individual.
Sometimes there is a lag period between when a cluster
crosses over and when the intervention can affect the out-
come in individuals. This may arise from a combination of
implementation lag (delay until the intervention is fully
implemented) and delay for the outcome to respond to
the intervention. In open or closed cohort SWTs, the step
length may be chosen so that the effect of the intervention
in the group of clusters that most recently crossed over
can be measured just before the next crossover point;
therefore the length needs to be greater than the lag
period. In a continuous recruitment short exposure
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SWT, the step length may be chosen to be large relative to
the implementation lag period, so that in the group that
most recently crossed over most outcome values from ex-
posure before the next crossover point will be contributed
by individuals exposed to the full intervention. Delay for
the outcome to respond is not relevant for the short expos-
ure continuous recruitment design, as individual follow-up
may be long and its length is unrelated to the steps.
We recommend first investigating constraints on the
number of steps and the minimum suitable step length
given the lag period. If given these, a number of steps
and step length can be found where the total trial dur-
ation is satisfactory and required sample size can be
achieved, given the number of clusters considered, then
the selections are finalised. This process can be iterative
because the sample size required will depend on the
number of steps [7]. Options described in the next section
can be considered if there are no satisfactory selections of
step length or duration.
In case study one it appears that the intervention has
minimal implementation lag, and there are no restrictions
on the number of steps, so the trial could be designed with
the maximum number of steps, and step length set simply
with the total trial duration and hence sample size in
mind. In case study two, though a closed cohort, outcome
data are obtained routinely so there are no restrictions on
the number of steps arising from cost or measurement
burden. The number of steps was, however, constrained to
be no more than four by the preference to implement the
intervention only at the start of school terms and conduct
the trial in one school year, and step length was likewise
constrained to be the length of the school term. With
careful advance planning and publicity for the interven-
tion, there need not be any implementation lag in case
study two, and neither does it seem likely there would be
any further delay for the intervention (providing breakfast)
to affect the outcome (school attendance). In case study
three there seems to have been no constraint on the num-
ber of steps, as data collection occurred at time points un-
related to steps. There was an implementation lag as staff
training was required, but once training was received there
seems no reason for a further delay for the intervention to
affect the outcome of hand hygiene compliance. Had the
implementation lag period been substantial (for example
10 weekly training sessions) and the more conventional
approach of measurements before crossover points been
taken, then it would have been natural to select step
length to be slightly greater (for example more than
10 weeks) and then investigate the number of steps and its
impact on sample size and power.
Design choice two: incomplete or complete design
In the preceding section we have seen that a complete
SWT may be of longer duration or fewer steps than wished,
because a long step length is selected due to a lag period.
Two approaches can be taken to shorten the step length,
and possibly also total trial length, albeit potentially result-
ing in requiring more clusters in the trial. The first is to
acknowledge the lag at the analysis stage [14], and is dis-
cussed by trialists in our companion paper [15]. Another
solution at the design stage is to not collect data from
clusters during the lag period, an incomplete design repre-
sented in Fig. 3 by Hemming et al. [3]. If measurements
are taken before crossover points in a closed or open cohort
SWT, then this approach allows the step length as selected
for a complete SWT to be halved, as now we wish two step
lengths to be greater than the lag period. This use of an
incomplete design is worthy of consideration whenever
there is a lag, that is, if the step duration for a complete
SWT is longer than desired.
Incomplete designs have also been proposed to avoid
measurement burden. For example in Fig. 2 of their paper,
Hemming et al. describes a design where data are obtained
from each cluster in the step before the crossover and for
two steps afterwards [3]. Likewise within our review, the
SWT conducted by Dreischulte et al. involves data collec-
tion from clusters only in certain periods before and after
the crossover [16]. We feel unable to recommend these
‘sparse’ designs, with potentially few clusters providing data
at each time point in the trial, until further confirmatory
methodological work is conducted, but acknowledge their
appeal.
Design choice three: randomisation method
Two common problems faced by CRTs are imbalance in
important characteristics across study arms despite rando-
mising the clusters (particularly where the number of clus-
ters randomised is small), and substantial reductions in
power resulting from between-cluster variation. Two ap-
proaches taken to reduce both of these problems are
matching and stratification [17]. Both approaches poten-
tially reduce the between-cluster variation and improve bal-
ance and must be taken account of in the analysis.
Stratification can also be used in the randomisation of the
order of cluster rollout for an SWT. If clusters are divided
into strata, the order of rollout can be randomised within
each stratum. The numbers of clusters across the strata do
not have to be equal. The Better Health Outcomes through
Mentoring and Assessment (BHOMA) study is an SWT of
a health systems strengthening intervention in Zambia,
conducted in 42 clusters divided into three districts. There
were seven clusters in district A, 14 clusters in district B,
and 21 clusters in district C, so at each crossover point one
cluster from district A, two from district B, and three from
district C crossed over from the control to intervention
[18]. As there were six clusters in each group, the stratifica-
tion of the randomisation of clusters to groups assured bal-
ance of districts across the order of rollout. Analysis for the
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BHOMA study will then include district as a fixed effect. In
this example, even though the numbers of clusters were un-
equal across strata, they were multiples of each other and
at least one cluster from each stratum switched to interven-
tion at each crossover point. This feature makes it feasible
to include categorical time effects in the analysis that can
be shared across strata, and hence simplifies the analysis.
The equivalent of matching for an SWT would only be pos-
sible for SWTs with two steps. One trial protocol found in
our review describes a more complex stratification, where
some strata will have only two steps and the SWT con-
ducted within strata may not overlap in time, resulting in a
complex data structure and analysis [19].
Another approach to improving baseline balance in
important variables for CRTs is restricted randomisa-
tion. In this approach, criteria for ‘reasonable’ baseline
balance across arms are chosen and only randomisa-
tions that satisfy these criteria are ‘acceptable’. One of
these acceptable randomisations is then chosen. Re-
stricted randomisation can also be applied to an SWT,
where the principle will be balance in the order of roll-
out, so that for example, the first half of clusters to
cross over are not the most or least likely to have the
outcome. Durovni et al. randomised 29 HIV clinics in
an SWT with a primary outcome of tuberculosis inci-
dence [20, 21]. Randomisation was restricted, such that
‘the sum of the covariate values weighted by the number of
months in the intervention status must be within cjx100 %
of that for control status’, where cj determines how restrict-
ive the criteria was, for six criteria: mean CD4 count, clinic
size, average education, tuberculosis treatment levels, exist-
ence of a supervised tuberculosis therapy programme, and
geography. For an SWT, in addition to determining how
many acceptable allocations there are, one must also check
whether any cluster is (almost) always allocated to the same
point in the rollout order (that is, to one particular group)
and whether any two clusters (almost) always appear in the
same group (as then they are equivalent to just one cluster).
A combination of stratified (for the variable most predictive
of between-cluster variation) and then restricted ran-
domisation (for other important variables) may be the best
approach, and will be particularly important in SWTs with
few clusters.
In a continuous recruitment short exposure design
stratification and restricted randomisation could be
based on characteristics of clusters, or of historical clus-
ter summary values of outcomes or other characteristics
of individuals within clusters. In a closed cohort design,
besides this information, it may be possible to use clus-
ter summary values of the characteristics of individuals
who will participate in the trial if these are known be-
fore randomisation. In an open cohort design it may
likewise be possible to use information from individuals
who will participate at the start of the trial.
Design choice four: collection of outcome data before or
after the rollout period
In the design literature [2], the ‘classic’ SWT design in-
cludes one step length of data collection before rollout
and one step length of data collection after rollout, as in
case study one. There are two reasons why we do not, in
general, recommend collecting (and then including in the
primary analysis) more data from longer periods before or
after rollout, particularly if this uses resources that could
be used to collect more data during the rollout period.
The first reason is that these data do not directly inform
the estimation of the intervention effect unless strong as-
sumptions are made concerning period effects before dur-
ing and after the rollout period, which is inadvisable.
Without such strong assumptions the gain in precision is
modest, arising from information concerning variability
between clusters. With increasing data before or after roll-
out the marginal gain in precision declines. The second
reason is that including these data may introduce bias un-
less the model for these data over the data collection
period is correctly specified, which is more difficult to do
as the period becomes longer. Collecting data well after
the rollout period may, however, be worthwhile if a sec-
ondary analysis of whether the intervention effect appears
to be sustained is very important.
In case study three it seems most data included in
analysis were collected before or after the rollout
period. It would appear that focussing data collection
on the rollout period, and perhaps extending the rollout
period, would have provided a more informative trial.
The collection of extensive data after the rollout period
did, however, permit a per-protocol analysis. Con-
versely, in case study two it seems that since outcome
data are routinely collected that data from immediately
before the rollout period could have been compiled and
included in analysis if the participants attended the
same school before the year of the trial.
Carry-over effects, bias, and individual exposure to one or
both conditions
Carry-over effects are widely discussed in the literature on
individually randomised crossover trials [22]. This design is
commonly used with individuals with a chronic condition
who are randomised to receiving a standard treatment for a
certain period followed by a new treatment, or vice versa.
Health is measured during each period to determine which
treatment is better, and there may be a ‘wash-out’ period
between the two treatments so that there will be no carry-
over effect of the first treatment during the second period.
The design is not normally recommended when carry-over
effects are anticipated. Carry-over effects are always consid-
ered, and can arise if the new treatment has a permanent
effect on the health of participants after a short period of
administration.
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Carry-over effects are the main reason why a crossover
design is usually not recommended for CRTs that involve
staff training interventions within health facilities. Staff
cannot be ‘untrained’: in clusters randomised to receive
the intervention first and the control condition afterwards,
a carry-over effect from the training is likely to influence
how patients will be managed, even when the intervention
is formally withdrawn.
The issue of carry-over effects seems to have received
very little attention in the literature on the SWT design,
because the crossover is always from control to interven-
tion, and so the obvious reasons to consider carry-over ef-
fects described earlier do not apply. Carry-over effects
may also seem unlikely because in some SWT the control
condition exists in the population before the trial, and so
all participants have already been exposed to the control
for so long that some additional exposure during the trial
is unimportant. But carry-over effects of a somewhat dif-
ferent nature can nevertheless apply, and we feel these
should always be considered, as in some cases the re-
sponse to the intervention may be affected by a cluster’s
duration in the control condition within the trial, or by
the individual’s duration in the control condition if indi-
viduals experience both conditions within the trial.
Individual carry-over effects need to be considered in
SWTs where many or all individuals experience both
control and intervention conditions. In an open or
closed cohort trial, carry-over effects can arise if the trial
is conducted in a population where the outcome may
not be stable. For example, in a trial of those diagnosed
with a health concern, health may change during the
control condition exposure, which could affect response
to the intervention. For example, participants may be-
come sicker through an extended period in the control
condition, and hence be unable to respond fully to an
improved treatment policy. This would lead to under-
estimation of the intervention effect. In our review we
saw that such effects could potentially arise in trials of
the management of diabetes [23, 24], amongst others. A
carry-over effect can also arise in a continuous recruit-
ment design if the exposure is of long duration: partici-
pants recruited during the control period for a cluster
may switch care to the intervention policy part-way
through. An example in our review compares methods
to manage patients diagnosed with pressure ulcers dur-
ing the trial [12].
Carry-over effects can also arise at the cluster level in
trials comparing methods to detect a health condition
and change its management. In such a scenario, the
number of undetected cases remaining in clusters may
decline over time. The types of undetected cases may
also change, for example because cases that are more
challenging to identify might remain undetected longer.
The intervention and control conditions could therefore
differ in how effectively cases are detected, and these
changes over time will be influenced by the duration of the
control condition. As the number and type of undetected
cases will likely affect response to intervention there can be
carry-over effects, most clearly in a closed cohort but also
in an open cohort, unless individuals leave and join clusters
at a high rate. This may be a concern in trials, such as one
addressing detection and improved management of patients
with multiple comorbidities and medications found in our
review [25], or another trial involving identifying and treat-
ing depression in nursing homes [26]. This problem of
changing participant distribution over time is most obvious
for time-to-event outcomes such as death, and analysis of
the intervention effect will be subject to survivor bias.
In case study two it seems unlikely that there will be a
carry-over effect. Specifically the attendance of pupils in
a term when the intervention is introduced (school
breakfasts) is unlikely to be affected by whether a school
had exposed pupils to the control condition (no break-
fast) for one or two more terms more than in other
schools. In case study three, carry-over effects are again
unlikely as the control condition is a standard approach
that staff will have experienced for a while before the
trial, and the outcome is likely to remain stable.
Designs such as the continuous recruitment short ex-
posure are more robust than the open or closed cohort
designs because each individual experiences only one
condition, so carry-over effects are less likely. Outcomes
under the intervention condition are estimated only
from individuals with no prior exposure to the control.
Discussion
We have identified a wide range of SWT designs, classi-
fied in terms of how individuals experience control and/or
intervention conditions, and how outcome measurements
are obtained. These features are largely determined dir-
ectly by the research question and setting. We have also
offered guidance for the choice of key design features that
are more directly under the control of researchers, such as
the randomisation method, the number of steps, and the
step length. This work describing the range of designs
contrasts with the previous SWT design literature, which
has generally focussed on designs where data are collected
cross-sectionally at discrete time points. As shown in our
review, these constitute only a minority of recently con-
ducted trials [1].
As part of our work describing the range of SWT designs
we have also outlined a set of features that researchers
should report when describing their trial: (i) how individ-
uals start their exposure; (ii) the duration of exposure; (iii)
how individual exposure is influenced by the crossing over
of the cluster to the intervention; (iv) how measurements
are obtained; and (iv) whether the timing of measurement
is linked to each individual’s exposure or to trial steps.
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Researchers may choose to use our suggested trial design
names of closed cohort, open cohort, and continuous re-
cruitment short exposure, but these do not replace provid-
ing a full description of exposure and measurement.
Figures such as 2a-c may help to describe these aspects,
particularly if the design is novel. We hope that describing
these characteristics will become standard along with de-
tails of the allocation, for which a figure such as Fig. 3a-c
is recommended, and the randomisation. This level of
reporting would give additional important detail for some
aspects beyond that recently suggested by others [8], and
should be considered for future guidelines [6].
In our review, most conducted trials did not raise
serious concerns for major carry-over effects, but it is
unclear whether these were considered. We have de-
scribed why the possibility of carry-over effects should
be considered for SWTs in which individuals experi-
ence both control and intervention conditions. The
continuous recruitment design is an attractive design
since each participant experiences only one condition,
and in many cases needs to provide only one outcome
measurement. The closed cohort design, with repeated
measurements on the same individual, may be prob-
lematic because individuals experience both condi-
tions, but it can be a very powerful design. In many
contexts, and in most trials in our review, it may be
considered that since participants have been exposed
to the control condition for a long time before the
trial, they are likely to be stable in relation to the pri-
mary outcome. In this case it is unlikely that exposure
to the control condition or duration on response to
intervention will be an issue, so the standard analysis
methods and interpretation will apply. Even if partici-
pants are stable at the start of the SWT, if the primary
outcome is time-to-event (or rate of detection of a
condition) then designs such as the closed cohort will
always be susceptible to survivor bias. SWT designs
where individuals experience both conditions may be a
good choice, given constraints and the research ques-
tion. In our opinion however, researchers should con-
sider the possibility of carry-over effects and other bias
a priori, and report these considerations when publish-
ing the results of the trial.
Importantly, we have noted that in some SWTs out-
come data are collected a long time before or after roll-
out, and then included in the primary analysis, such as
in case study three. We think that this is generally inad-
visable [14], and recommend collecting such data only if
this does not reduce the data collected during the rollout
period. Furthermore we suggest these data should be
used only in an informal assessment of how the inter-
vention changed the time trend of the outcome seen be-
fore rollout, or of whether the intervention effect is
sustained beyond the rollout period.
Incomplete designs have been proposed in which data
are not collected from all clusters at all times. These de-
signs may be chosen to reduce cost and measurement bur-
den or to reduce step length when there is a lag period
between when a cluster crosses over and when the inter-
vention can affect the outcome in individuals, so as to fa-
cilitate more steps in the trial or even a shorter overall trial
length (whilst possibly increasing the number of clusters in
the trial). Further work in this area might address other ap-
proaches to restricting the burden of measurement, for ex-
ample collecting data from all clusters at all measurement
times but varying the proportions of participants mea-
sured, so that measurement is unbalanced across clusters.
One appealing option worthy of consideration could be to
take measurements from a low proportion of participants
from clusters in the exposure condition that is predomin-
ant at the time, that is, the proportion in intervention clus-
ters would be high at the start, low at the end, and the
same proportion as control clusters in the middle of roll-
out. This sampling option would increase the power from
a ‘vertical’ analysis of the data [14].
We believe that a well-conducted SWT, in which par-
ticipants experience only one condition and analysis ap-
propriately takes account of period effects, provides
strong evidence concerning the effectiveness of an inter-
vention, and that this evidence will be far stronger than
that from a non-randomised rollout. In our view, such
a carefully designed and analysed SWT can in principle
be as rigorous as a standard CRT, and deserves to be
viewed as an experimental design rather than quasi-
experimental. The quality of evidence provided by an
SWT is a controversial topic, but we hope that this de-
bate will become more nuanced, recognising that the
SWT is a family of different designs which each have
strengths and weaknesses.
Conclusions
There is a wide range of stepped wedge trial designs,
and key aspects such as the exposure of individuals and
their measurement should be reported more clearly.
Currently, simple randomisation is predominantly used,
but researchers should consider the use of stratified and/
or restricted randomisation. Trials should generally not
commit resources to collect outcome data from individ-
uals exposed a long time before or after the rollout
period because these data contribute little to the primary
analysis unless strong assumptions are made. Incomplete
designs have been proposed and can allow a more flexible
choice of the number of steps and step length. Though
substantial carry-over effects are uncommon in stepped
wedge trials, researchers should consider their possibility
before conducting a trial in which individuals experience
both control and intervention conditions, such as a closed
or open cohort trial.
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